Fmr LLC cut its holdings in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 1.9% in the 4th quarter, HoldingsChannel reports. The fund owned 2,414,932 shares of the company’s stock after selling 45,714 shares during the period. Fmr LLC owned approximately 0.06% of Intellia Therapeutics worth $32,964,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of the company. BlackRock Inc. increased its position in shares of Intellia Therapeutics by 4.5% during the fourth quarter. BlackRock Inc. now owns 2,868,738 shares of the company’s stock worth $39,158,000 after acquiring an additional 124,341 shares in the last quarter. Vanguard Group Inc. grew its position in Intellia Therapeutics by 12.2% in the 3rd quarter. Vanguard Group Inc. now owns 2,653,165 shares of the company’s stock worth $75,934,000 after purchasing an additional 287,682 shares in the last quarter. Vanguard Group Inc grew its position in Intellia Therapeutics by 12.2% in the 3rd quarter. Vanguard Group Inc now owns 2,653,165 shares of the company’s stock worth $75,934,000 after purchasing an additional 287,682 shares in the last quarter. Ontario Teachers Pension Plan Board bought a new stake in Intellia Therapeutics in the 4th quarter worth about $22,659,000. Finally, Federated Investors Inc. PA grew its position in Intellia Therapeutics by 6.8% in the 3rd quarter. Federated Investors Inc. PA now owns 667,525 shares of the company’s stock worth $19,105,000 after purchasing an additional 42,225 shares in the last quarter. 69.64% of the stock is owned by institutional investors.
In related news, EVP Andrew Schiermeier bought 7,500 shares of Intellia Therapeutics stock in a transaction dated Wednesday, March 6th. The stock was purchased at an average cost of $15.72 per share, with a total value of $117,900.00. Following the transaction, the executive vice president now directly owns 3,250 shares of the company’s stock, valued at $51,090. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 3.20% of the stock is owned by corporate insiders.
A number of brokerages have issued reports on NTLA. BidaskClub downgraded shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, April 16th. Evercore ISI began coverage on shares of Intellia Therapeutics in a research report on Thursday, April 11th. They issued an “outperform” rating for the company. Zacks Investment Research downgraded shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 29th. Chardan Capital reaffirmed a “buy” rating and issued a $57.50 price objective on shares of Intellia Therapeutics in a research report on Wednesday, February 27th. Finally, BTIG Research began coverage on shares of Intellia Therapeutics in a research report on Thursday, February 7th. They issued a “buy” rating and a $20.00 price objective for the company. Eight equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $29.08.
Intellia Therapeutics stock opened at $16.15 on Friday. Intellia Therapeutics Inc has a twelve month low of $11.03 and a twelve month high of $32.95. The company has a market cap of $730.38 million, a PE ratio of -8.16 and a beta of 2.95.
Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Wednesday, February 27th. The company reported ($0.43) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.12. Intellia Therapeutics had a negative net margin of 280.42% and a negative return on equity of 30.59%. The firm had revenue of $7.90 million during the quarter, compared to the consensus estimate of $9.92 million. During the same period in the prior year, the firm earned ($0.61) EPS. The company’s revenue was up 17.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Intellia Therapeutics Inc will post -2.47 earnings per share for the current fiscal year.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Featured Story: Relative Strength Index
Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics Inc (NASDAQ:NTLA).
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.